Validation of single nucleotide polymorphisms potentially related to R-CHOP resistance in diffuse large B-cell lymphoma patients

Abstract

Aim: Diffuse large B-cell lymphoma (DLBCL) is the most common B-cell non-Hodgkin lymphoma (NHL). Despite the availability of clinical and molecular algorithms applied for the prediction of prognosis, in up to 30%-40% of patients, intrinsic or acquired drug resistance occurs. Constitutional genetics may help to predict R-CHOP resistance. This study aimed to validate previously identified single nucleotide polymorphisms (SNPs) in the literature as potential predictors of R-CHOP resistance in DLBCL patients, SNPs.

Methods: Twenty SNPs, involved in R-CHOP pharmacokinetics/pharmacodynamics or other pathobiological processes, were investigated in 185 stage I-IV DLBCL patients included in a multi-institution pharmacogenetic study to validate their previously identified correlations with resistance to R-CHOP.

Results: Correlations between rs2010963 (VEGFA gene) and sex (P = 0.046), and rs1625895 (TP53 gene) and stage (P = 0.003) were shown. After multivariate analyses, a concordant effect (i.e., increased risk of disease progression and death) was observed for rs1883112 (NCF4 gene) and rs1800871 (IL10 gene). When patients were grouped according to the revised International Prognostic Index (R-IPI), both these SNPs further discriminated progression-free survival (PFS) and overall survival (OS) of the R-IPI-1-2 subgroup. Overall, patients harboring the rare allele showed shorter PFS and OS compared with wild-type patients.

Conclusions: Two out of the 20 study SNPs were validated. Thus, these results support the role of previously identified rs1883112 and rs1800871 in predicting DLBCL resistance to R-CHOP and highlight their ability to further discriminate the prognosis of R-IPI-1-2 patients. These data point to the need to also focus on host genetics for a more comprehensive assessment of DLBCL patient outcomes in future prospective trials.

Keywords

Diffuse large B-cell lymphoma (DLBCL) / R-CHOP regimen / host genetics / single nucleotide polymorphism (SNP) / biomarkers / tumor drug resistance

References

[1] Siegel RL,Wagle NS.Cancer statistics, 2023.CA Cancer J Clin2023;73:17-48

[2] Alaggio R,Anagnostopoulos I.Correction: “The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720-1748.Leukemia2023;37:1944-51 PMCID:PMC10457187

[3] Campo E,Cook JR.The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022;140(11):1229-1253.Blood2023;141:437 PMCID:PMC10023734

[4] Alizadeh AA,Davis RE.Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.Nature2000;403:503-11

[5] Chapuy B,Dunford AJ.Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.Nat Med2018;24:679-90 PMCID:PMC6613387

[6] Schmitz R,Huang DW.Genetics and pathogenesis of diffuse large B-cell lymphoma.N Engl J Med2018;378:1396-407 PMCID:PMC6010183

[7] Lacy SE,Beer PA.Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report.Blood2020;135:1759-71 PMCID:PMC7259825

[8] Hans CP,Greiner TC.Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.Blood2004;103:275-82

[9] Riedell PA.Double hit and double expressors in lymphoma: definition and treatment.Cancer2018;124:4622-32

[10] National Comprehensive Cancer Network (NCCN). NCCN Guidelines. B-Cell Lymphomas. Version 2.2024. Available from: https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf. [Last accessed on 21 May 2024]

[11] International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma.N Engl J Med1993;329:987-94

[12] Miller TP,Cassady JR.Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma.N Engl J Med1998;339:21-6

[13] Sehn LH,Chhanabhai M.The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.Blood2007;109:1857-61

[14] Coiffier B,Briere J.CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.N Engl J Med2002;346:235-42

[15] Sehn LH,Chhanabhai M.Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.J Clin Oncol2005;23:5027-33

[16] Pfreundschuh M, Trümper L, Osterborg A, et al; MabThera International Trial Group. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379-91.

[17] Coiffier B,Van Den Neste E.Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte.Blood2010;116:2040-5 PMCID:PMC2951853

[18] Pfreundschuh M, Kuhnt E, Trümper L, et al; MabThera International Trial (MInT) Group. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 2011;12:1013-22.

[19] Pfreundschuh M, Schubert J, Ziepert M, et al; German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9:105-16.

[20] Cunningham D,Jack A.Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.Lancet2013;381:1817-26

[21] Tilly H,Sehn LH.Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma.N Engl J Med2022;386:351-63

[22] Wilson WH,Pittaluga S.Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers.J Clin Oncol2008;26:2717-24 PMCID:PMC2409217

[23] Bartlett NL,Jung SH.Dose-adjusted EPOCH-R compared With R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial alliance/CALGB 50303.J Clin Oncol2019;37:1790-9 PMCID:PMC6774813

[24] Friedberg JW.How I treat double-hit lymphoma.Blood2017;130:590-6

[25] Duarte C.Management considerations for patients with primary refractory and early relapsed diffuse large B-cell lymphoma.Am Soc Clin Oncol Educ Book2023;43:e390802

[26] Park YH,Kim JG.Interaction between BCL2 and interleukin-10 gene polymorphisms alter outcomes of diffuse large B-cell lymphoma following rituximab plus CHOP chemotherapy.Clin Cancer Res2009;15:2107-15

[27] Rossi D,Franceschetti S.Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21.Leukemia2009;23:1118-26

[28] Voropaeva EN,Pospelova TI.Prognostic impact of the TP53 rs1625895 polymorphism in DLBCL patients.Br J Haematol2015;169:32-5

[29] Liu D,Sun H.ABCG2 and NCF4 polymorphisms are associated with clinical outcomes in diffuse large B-cell lymphoma patients treated with R-CHOP.Oncotarget2017;8:58292-303 PMCID:PMC5601652

[30] Brito ABC,Fanelli MF.Angiogenesis’ related genetic variants alter clinical features and prognosis of diffuse large B-cell lymphoma patients.Tumour Biol2021;43:129-40

[31] Broecker-Preuss M,Müller SP.Impact of germline polymorphisms in genes regulating glucose uptake on positron emission tomography findings and outcome in diffuse large B-cell lymphoma: results from the PETAL trial.J Cancer Res Clin Oncol2022;148:2611-21 PMCID:PMC9470686

[32] Narendra G,Raju B,Silakari O.Role of genetic polymorphisms in drug-metabolizing enzyme-mediated toxicity and pharmacokinetic resistance to anti-cancer agents: a review on the pharmacogenomics aspect.Clin Pharmacokinet2022;61:1495-517

[33] Nobili S,Mazzei T.Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression.Med Res Rev2012;32:1220-62

[34] Nobili S,Landini I,Roviello G.Role of ATP-binding cassette transporters in cancer initiation and progression.Semin Cancer Biol2020;60:72-95

[35] Zheng H,Zheng Y.Correction: Zhang et al. Glycolysis-related SLC2A1 is a potential pan-cancer biomarker for prognosis and immunotherapy. Cancers 2022, 14, 5344.Cancers2023;15:586 PMCID:PMC9913489

[36] Hayes JD.The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance.Crit Rev Biochem Mol Biol1995;30:445-600

[37] Rezvani AR.Rituximab resistance.Best Pract Res Clin Haematol2011;24:203-16 PMCID:PMC3113665

[38] De Mattia E, Cecchin E, Toffoli G. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: toward targeted personalized therapy.Drug Resist Updat2015;20:39-70

[39] Refae S,Brest P.Germinal immunogenetics as a predictive factor for immunotherapy.Crit Rev Oncol Hematol2019;141:146-52

[40] De Mattia E,Guardascione M.Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.World J Gastroenterol2019;25:3870-96 PMCID:PMC6689804

[41] Szkandera J,Dandachi N.Analysis of functional germline polymorphisms for prediction of response to anthracycline-based neoadjuvant chemotherapy in breast cancer.Mol Genet Genomics2012;287:755-64

[42] Hlavac V,Elsnerova K.Use of germline genetic variability for prediction of chemoresistance and prognosis of breast cancer patients.Cancers2018;10:511 PMCID:PMC6316878

[43] Xiao Q,Winter S.Germline variant burden in multidrug resistance transporters is a therapy-specific predictor of survival in breast cancer patients.Int J Cancer2020;146:2475-87

[44] Windsor RE,Kallis C,Whelan JS.Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study.Cancer2012;118:1856-67

[45] Macauda A,Buda G.Inherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patients.Br J Haematol2018;183:375-84

[46] Labriet A,De Mattia E.Combination of germline variations associated with survival of folinic acid, fluorouracil and irinotecan-treated metastatic colorectal cancer patients.Pharmacogenomics2019;20:1179-87

[47] Innocenti F,Patil SA.Genomic analysis of germline variation associated with survival of patients with colorectal cancer treated with chemotherapy plus biologics in CALGB/SWOG 80405 (alliance).Clin Cancer Res2021;27:267-75 PMCID:PMC7785628

[48] Galván-Femenía I,Duran X.Genomic profiling in advanced stage non-small-cell lung cancer patients with platinum-based chemotherapy identifies germline variants with prognostic value in SMYD2.Cancer Treat Res Commun2018;15:21-31

[49] Rumiato E,Malacrida S.A germline predictive signature of response to platinum chemotherapy in esophageal cancer.Transl Res2016;171:29-37.e1

[50] Gallagher DJ,Hamilton RJ.Germline single nucleotide polymorphisms associated with response of urothelial carcinoma to platinum-based therapy: the role of the host.Ann Oncol2013;24:2414-21

[51] Radtke S,Renner B.Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia.Blood2013;121:5145-53

[52] Shinozuka K,Jones RB,Nieto Y.Impact of polymorphic variations of gemcitabine metabolism, DNA damage repair, and drug-resistance genes on the effect of high-dose chemotherapy for relapsed or refractory lymphoid malignancies.Biol Blood Marrow Transplant2016;22:843-9 PMCID:PMC5703203

[53] Guan S,Chen Y.FOXM1 variant contributes to gefitinib resistance via activating Wnt/β-catenin signal pathway in patients with non-small cell lung cancer.Clin Cancer Res2022;28:3770-84

[54] Ravegnini G,Simeon V.An exploratory study by DMET array identifies a germline signature associated with imatinib response in gastrointestinal stromal tumor.Pharmacogenomics J2019;19:390-400

[55] Lavacchi D,Perrone G,Mini E.Pharmacogenetics in diffuse large B-cell lymphoma treated with R-CHOP: still an unmet challenge.Pharmacol Ther2022;229:107924

[56] Falduto A,Speciale A.How gene polymorphisms can influence clinical response and toxicity following R-CHOP therapy in patients with diffuse large B cell lymphoma.Blood Rev2017;31:235-49

[57] Perrone G,Urru S.Exploratory genome-wide association analysis to identify pharmacogenetic determinants of response to R-CHOP in diffuse large B-cell lymphoma.Cancers2023;15:2753 PMCID:PMC10216814

[58] Hlaváč V,Souček P.Pharmacogenomics to predict tumor therapy response: a focus on ATP-binding cassette transporters and cytochromes P450.J Pers Med2020;10:108 PMCID:PMC7565825

[59] Jiang B,Wu Q.ABCB1 (C1236T) polymorphism affects P-glycoprotein-mediated transport of methotrexate, doxorubicin, actinomycin D, and etoposide.DNA Cell Biol2019;38:485-90

[60] Hu LL,Chen X.BCRP gene polymorphisms are associated with susceptibility and survival of diffuse large B-cell lymphoma.Carcinogenesis2007;28:1740-4

[61] Atanaskovic L,Tarabar O.Clinical implications of glutathione S-transferase genotyping in patients with diffuse large B-cell lymphoma.J BUON2016;21:1459-65

[62] Jordheim LP,Ghesquieres H.Single nucleotide polymorphisms in ABCB1 and CBR1 can predict toxicity to R-CHOP type regimens in patients with diffuse non-Hodgkin lymphoma.Haematologica2015;100:e204-6 PMCID:PMC4420233

[63] Chae YS,Sohn SK.Lymphotoxin alfa and receptor-interacting protein kinase 1 gene polymorphisms may correlate with prognosis in patients with diffuse large B cell lymphoma treated with R-CHOP.Cancer Chemother Pharmacol2010;65:571-7

[64] Liu D,Dong M.Polymorphisms in cytokine genes as prognostic markers in diffuse large B cell lymphoma patients treated with (R)-CHOP.Ann Hematol2017;96:227-35

[65] Kim MK,Chi HS.VEGFA and VEGFR2 genetic polymorphisms and survival in patients with diffuse large B cell lymphoma.Cancer Sci2012;103:497-503 PMCID:PMC7713612

[66] 1000 Genomes Project Consortium; Auton A, Brooks LD, Durbin RM, et al. A global reference for human genetic variation. Nature 2015;526:68-74. PMCID:PMC4750478

[67] Martner A,Hellstrand K.NOX2 in autoimmunity, tumor growth and metastasis.J Pathol2019;247:151-4 PMCID:PMC6587556

[68] Gustafson HL,Goldman BH.Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma.Am J Hematol2014;89:639-45 PMCID:PMC4137041

[69] Alas S,Bonavida B.Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin’s lymphoma to apoptosis.Clin Cancer Res2001;7:709-23

[70] Stevens A,Brenchley PE,Ray DW.Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter.Cancer Res2003;63:812-6

[71] Lu TX,Xu W.TP53 dysfunction in diffuse large B-cell lymphoma.Crit Rev Oncol Hematol2016;97:47-55

[72] Hientz K,Bhakta-Guha D.The role of p53 in cancer drug resistance and targeted chemotherapy.Oncotarget2017;8:8921-46 PMCID:PMC5352454

[73] Kochethu G,Pepper C.Two germ line polymorphisms of the tumour suppressor gene p53 may influence the biology of chronic lymphocytic leukaemia.Leuk Res2006;30:1113-8